The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy
Open accessAbstract
Background The main obstacle to elucidating the role of CD4+ T cells in allergen-specific immunotherapy has been the absence of an adequately sensitive approach to directly characterize rare allergen-specific T cells without introducing substantial phenotypic modifications by in vitro amplification. Objective To monitor in physiological conditions, the allergen-specific CD4+ T cells generated during natural pollen exposure and during allergy vaccine. Methods Alder pollen allergy was used as a model for studying seasonal allergies. Allergen-specific CD4+ T cells were tracked and characterized in twelve alder pollen-allergic, six non-allergic and nine allergy vaccine-treated individuals using peptide-MHC class II tetramers. Results Allergen-specific CD4+ T cells were detected in all of the alder pollen-allergic and non-allergic subjects tested. Pathogenic responses (CRTH2 expression and TH2-cytokine production) are specifically associated with terminally differentiated (CD27−) allergen-specific CD4+ T cells, which dominate in allergic individuals but are absent in non-allergic individuals. In contrast, CD27 expressing allergen-specific CD4+ T cells are present at low frequencies in both allergic and non-allergic individuals and reflect classical features of the protective immune response with high expression of IL-10 and IFN-γ. Restoration of a protective response during allergen-specific immunotherapy appears to be due to the preferential deletion of pathogenic (CD27−) allergen-specific CD4+ T cells accompanied by IL-10 induction in surviving CD27+ allergen-specific CD4+ T cells. Conclusions Differentiation stage divides allergen-specific CD4+ T cells into two distinct subpopulations with unique functional properties and different fates during allergen-specific immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells
Acosta-Rodriguez, E. V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M., Lanzavecchia, A., Sallusto, F., & Napolitani, G. (2007) · Nature Immunology · doi:10.1038/ni1467 · Cited by 1,828
Sublingual immunotherapy for allergic rhinitis: systematic review and meta‐analysis*
Wilson, D. R., Torres Lima, M., & Durham, S. R. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00699.x · Cited by 660
Cited by
Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
Werfel, T., Allam, J.-P., Biedermann, T., Eyerich, K., Gilles, S., Guttman-Yassky, E., Hoetzenecker, W., Knol, E., Simon, H.-U., Wollenberg, A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.010 · Cited by 594
Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers
Shamji, M. H., & Durham, S. R. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.010 · Cited by 446
Burks, A. W., Calderon, M. A., Casale, T., Cox, L., Demoly, P., Jutel, M., Nelson, H., & Akdis, C. A. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.01.049 · Cited by 438
CD4 + T-cell subsets in inflammatory diseases: beyond the T h 1/T h 2 paradigm
Hirahara, K., & Nakayama, T. (2016) · International Immunology · doi:10.1093/intimm/dxw006 · Cited by 417
Allergen immunotherapy: past, present and future
Durham, S. R., & Shamji, M. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00786-1 · Cited by 413
Metadata
- Authors
- Wambre, E., DeLong, J. H., James, E. A., LaFond, R. E., Robinson, D., & Kwok, W. W.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 129
- Issue
- 2
- Pages
- 544-551.e7
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2005724569
- Cited by
- 170
- References
- 3
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.